Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma



Summary

Daratumumab refractoriness significantly worsens outcomes after CAR T-cell therapy in patients with relapsed/refractory multiple myeloma. Studies show these patients have reduced overall response rates, progression-free survival, and overall survival compared to daratumumab-sensitive patients. The mechanisms behind this are complex, possibly involving T-cell exhaustion, impaired CAR T-cell expansion/persistence, and a less favorable tumor microenvironment due to prior daratumumab exposure. Overcoming daratumumab refractoriness is a critical unmet need to improve CAR T-cell therapy efficacy in this challenging patient population, warranting further research into alternative treatment strategies and combinations.

Read more…

Credits: Source

This post is part of “Science/Immunology News”, Follow for more…!!!